{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:00:53Z","timestamp":1760061653801},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s12272-012-0613-x","type":"journal-article","created":{"date-parts":[[2012,6,29]],"date-time":"2012-06-29T09:39:42Z","timestamp":1340962782000},"page":"1055-1064","source":"Crossref","is-referenced-by-count":4,"title":["Effects of furanocoumarins in Kampo extract-based medicines on rat intestinal absorption of CYP3A and P-glycoprotein substrate drugs in vivo"],"prefix":"10.1007","volume":"35","author":[{"given":"Kazunori","family":"Iwanaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Arimune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makio","family":"Shibano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiye","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masawo","family":"Kakemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,30]]},"reference":[{"key":"613_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijpharm.2002.12.002","volume":"277","author":"L. Z. Benet","year":"2004","unstructured":"Benet, L. Z., Cummins, C. L., and Wu, C. Y., Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm., 277, 3\u20139 (2004).","journal-title":"Int. J. Pharm."},{"key":"613_CR2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.86.2.695","volume":"86","author":"C. Cordon-Cardo","year":"1989","unstructured":"Cordon-Cardo, C., O\u2019Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., and Bertino, J. R., Multidrug-resistance gene (P-glycoprotein) is expressed by en dothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U. S. A., 86, 695\u2013698 (1989).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"613_CR3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/38.9.1974900","volume":"38","author":"C. Cordon-Cardo","year":"1990","unstructured":"Cordon-Cardo, C., O\u2019Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., and Melamed, M. R., Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem., 38, 1277\u20131287 (1990).","journal-title":"J. Histochem. Cytochem."},{"key":"613_CR4","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1002\/jps.20975","volume":"96","author":"W. V. Castro de","year":"2007","unstructured":"de Castro, W. V., Mertens-Talcott, S., Derendorf, H., and Butterweck, V., Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J. Pharm. Sci., 96, 2808\u20132817 (2007).","journal-title":"J. Pharm. Sci."},{"key":"613_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1067\/mcp.2002.121152","volume":"71","author":"G. K. Dresser","year":"2002","unstructured":"Dresser, G. K., Bailey, D. G., Leake, B. F., Schwarz, U. I., Dawson, P. A., Freeman, D. J., and Kim, R. B., Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther., 71, 11\u201320 (2002).","journal-title":"Clin. Pharmacol. Ther."},{"key":"613_CR6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ejps.2006.04.010","volume":"29","author":"G. Englund","year":"2006","unstructured":"Englund, G., Rorsman, F., R\u00f6nnblom, A., Karlbom, U., Lazorova, L., Gr\u00e5sj\u00f6, J., Kindmark, A., and Artursson, P., Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci., 29, 269\u2013277 (2006).","journal-title":"Eur. J. Pharm. Sci."},{"key":"613_CR7","first-page":"766","volume":"28","author":"L. Q. Guo","year":"2000","unstructured":"Guo, L. Q., Fukuda, K., Ohta, T., and Yamazoe, Y., Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab. Dispos., 28, 766\u2013771 (2000a).","journal-title":"Drug Metab. Dispos."},{"key":"613_CR8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1254\/jjp.82.122","volume":"82","author":"L. Q. Guo","year":"2000","unstructured":"Guo, L. Q., Taniguchi, M., Xiao, Y. Q., Baba, K., Ohta, T., and Yamazoe, Y., Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity. Jpn. J. Pharmacol., 82, 122\u2013129 (2000b).","journal-title":"Jpn. J. Pharmacol."},{"key":"613_CR9","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1124\/dmd.110.032847","volume":"38","author":"K. Iwanaga","year":"2010","unstructured":"Iwanaga, K., Hayashi, M., Hamahata, Y., Miyazaki, M., Shibano, M., Taniguchi, M., Baba, K., and Kakemi, M., Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein. Drug Metab. Dispos., 38, 1286\u20131294 (2010a).","journal-title":"Drug Metab. Dispos."},{"key":"613_CR10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijpharm.2009.12.045","volume":"388","author":"K. Iwanaga","year":"2010","unstructured":"Iwanaga, K., Sumizawa, T., Miyazaki, M., and Kakemi, M., Characterization of organogel as a novel oral controlled release formulation for lipophilic compounds. Int. J. Pharm., 388, 123\u2013128 (2010b).","journal-title":"Int. J. Pharm."},{"key":"613_CR11","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1248\/bpb.34.1246","volume":"34","author":"K. Iwanaga","year":"2011","unstructured":"Iwanaga, K., Yoneda, S., Hamahata, Y., Miyazaki, M., Shibano, M., Taniguchi, M., Baba, K., and Kakemi, M., Inhibitory effects of furanocoumarin derivatives in Kampo extract medicines on P-glycoprotein at the blood-brain barrier. Biol. Pharm. Bull., 34, 1246\u20131251 (2011).","journal-title":"Biol. Pharm. Bull."},{"key":"613_CR12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1248\/bpb.28.316","volume":"28","author":"M. Kageyama","year":"2005","unstructured":"Kageyama, M., Namiki, H., Fukushima, H., Ito, Y., Shibata, N., and Takada, K., In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol. Pharm. Bull., 28, 316\u2013322 (2005).","journal-title":"Biol. Pharm. Bull."},{"key":"613_CR13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clpt.2004.02.007","volume":"75","author":"S. M. Kakar","year":"2004","unstructured":"Kakar, S. M., Paine, M. F., Stewart, P. W., and Watkins, P. B., 6\u2033-Dihydroxybergamottin contributes to the grapefruit juice effect. Clin. Pharmacol. Ther., 75, 569\u2013579 (2004).","journal-title":"Clin. Pharmacol. Ther."},{"key":"613_CR14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/00498250500093786","volume":"35","author":"T. Kanazu","year":"2005","unstructured":"Kanazu, T., Okamura, N., Yamaguchi, Y., Baba, T., and Koike, M., Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. Xenobiotica, 35, 305\u2013317 (2005).","journal-title":"Xenobiotica"},{"key":"613_CR15","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/jps.21618","volume":"98","author":"Y. Kato","year":"2009","unstructured":"Kato, Y., Miyazaki, T., Kano, T., Sugiura, T., Kubo, Y., and Tsuji, A., Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J. Pharm. Sci., 98, 2529\u20132539 (2009).","journal-title":"J. Pharm. Sci."},{"key":"613_CR16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.surg.2009.06.012","volume":"146","author":"T. Kono","year":"2009","unstructured":"Kono, T., Kanematsu, T., and Kitajima, M., Exodus of Kampo, traditional Japanese medicine, from the complementary and alternative medicines: is it time yet? Surgery, 146, 837\u2013840 (2009).","journal-title":"Surgery"},{"key":"613_CR17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clpt.2005.11.001","volume":"79","author":"G. L. Lemma","year":"2006","unstructured":"Lemma, G. L., Wang, Z., Hamman, M. A., Zaheer, N. A., Gorski, J. C., and Hall, S. D., The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin. Pharmacol. Ther., 79, 218\u2013230 (2006).","journal-title":"Clin. Pharmacol. Ther."},{"key":"613_CR18","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1124\/dmd.106.013342","volume":"35","author":"Y. Meier","year":"2007","unstructured":"Meier, Y., Eloranta, J. J., Darimont, J., Ismair, M. G., Hiller, C., Fried, M., Kullak-Ublick, G. A., and Vavricka, S. R., Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab. Dispos., 35, 590\u2013594 (2007).","journal-title":"Drug Metab. Dispos."},{"key":"613_CR19","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajcn\/83.5.1097","volume":"83","author":"M. F. Paine","year":"2006","unstructured":"Paine, M. F., Widmer, W. W., Hart, H. L., Pusek, S. N., Beavers, K. L., Criss, A. B., Brown, S. S., Thomas, B. F., and Watkins, P. B., A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am. J. Clin. Nutr., 83, 1097\u20131105 (2006).","journal-title":"Am. J. Clin. Nutr."},{"key":"613_CR20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/BF01059549","volume":"8","author":"S. Riegelman","year":"1980","unstructured":"Riegelman, S. and Collier, P., The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J. Pharmacokinet. Biopharm., 8, 509\u2013534 (1980).","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"613_CR21","first-page":"1228","volume":"25","author":"P. Schmiedlin-Ren","year":"1997","unstructured":"Schmiedlin-Ren, P., Edwards, D. J., Fitzsimmons, M. E., He, K., Lown, K. S., Woster, P. M., Rahman, A., Thummel, K. E., Fisher, J. M., Hollenberg, P. F., and Watkins, P. B., Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos., 25, 1228\u20131233 (1997).","journal-title":"Drug Metab. Dispos."},{"key":"613_CR22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5414\/CPP38161","volume":"38","author":"U. I. Schwarz","year":"2000","unstructured":"Schwarz, U. I., Gramatt\u00e9, T., Krappweis, J., Oertel, R., and Kirch, W., P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int. J. Clin. Pharmacol. Ther., 38, 161\u2013167 (2000).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"613_CR23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clpt.2004.11.111","volume":"77","author":"U. I. Schwarz","year":"2005","unstructured":"Schwarz, U. I., Seemann, D., Oertel, R., Miehlke, S., Kuhlisch, E., Fromm, M. F., Kim, R. B., Bailey, D. G., and Kirch, W., Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin. Pharmacol. Ther., 77, 291\u2013301 (2005).","journal-title":"Clin. Pharmacol. Ther."},{"key":"613_CR24","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11095-008-9771-4","volume":"26","author":"Y. Shirasaka","year":"2009","unstructured":"Shirasaka, Y., Li, Y., Shibue, Y., Kuraoka, E., Spahn-Langguth, H., Kato, Y., Langguth, P., and Tamai, I., Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by pglycoprotein and organic anion transporting polypeptide (Oatp). Pharm. Res., 26, 560\u2013567 (2009).","journal-title":"Pharm. Res."},{"key":"613_CR25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.109.159756","volume":"332","author":"Y. Shirasaka","year":"2010","unstructured":"Shirasaka, Y., Kuraoka, E., Spahn-Langguth, H., Nakanishi, T., Langguth, P., and Tamai, I., Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J. Pharmacol. Exp. Ther., 332, 181\u2013189 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"613_CR26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1067\/mcp.2000.107579","volume":"68","author":"K. Westphal","year":"2000","unstructured":"Westphal, K., Weinbrenner, A., Giessmann, T., Stuhr, M., Franke, G., Zschiesche, M., Oertel, R., Terhaag, B., Kroemer, H. K., and Siegmund, W., Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin. Pharmacol. Ther., 68, 6\u201312 (2000).","journal-title":"Clin. Pharmacol. Ther."},{"key":"613_CR27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/147323000603400301","volume":"34","author":"F. Yu","year":"2006","unstructured":"Yu, F., Takahashi, T., Moriya, J., Kawaura, K., Yamakawa, J., Kusaka, K., Itoh, T., Morimoto, S., Yamaguchi, N., and Kanda, T., Traditional Chinese medicine and Kampo: a review from the distant past for the future. J. Int. Med. Res., 34, 231\u2013239 (2006).","journal-title":"J. Int. Med. Res."}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-012-0613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12272-012-0613-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-012-0613-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T11:28:39Z","timestamp":1561894119000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12272-012-0613-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1007\/s12272-012-0613-x","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}